SystImmune’s pipeline includes bi-specific antibodies, tri-specific antibodies, and antibody-drug conjugates (ADCs).
Bi-specific antibodies for the treatment of non-small cell lung cancer. We have completed our small scale process development and are now into a pilot scale production run in preparation for phase I clinical trials. We expect to file an IND at the end of 2017 in the US and in early 2018 in China.
Bi-specific antibodies against two checkpoint inhibitors: We are currently expecting to file our IND in late 2018 in both the US and China.